Gene:
KCNH2
potassium voltage-gated channel, subfamily H (eag-related), member 2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1137617 11243821A>G, 150648198A>G, 1956 C>T, 1956T>C, 31817T>C, 936T>C, Tyr312=, Tyr652=
A > C
A > G
Stop Codon
Tyr312null
Tyr312Tyr
rs12720441 11242927G>A, 11242927G>C, 1330C>G, 1330C>T, 150647304G>A, 150647304G>C, 2350C>G, 2350C>T, 32711C>G, 32711C>T, Arg444Gly, Arg444Trp, Arg784Gly, Arg784Trp, R784W
G > C
G > A
Missense
Arg444Trp
rs1805123 11241157T>G, 150645534T>G, 1670A>C, 2690A>C, 34481A>C, K897T, KCNH2:K897T, Lys557Thr, Lys897Thr
T > G
Missense
Lys557Thr
rs36210421 11240051C>A, 150644428C>A, 2120G>T, 3140G>T, 35587G>T, Arg1047Leu, Arg707Leu, KCNH2: R1047L, R1047L
C > A
Missense
Arg707Leu
rs3807375 11262833C>T, 12805G>A, 150667210C>T, 307+4589G>A, KCNH2:rs3807375
C > T
Intronic
rs3815459 11240017C>T, 150644394C>T, 2132+22G>A, 3152+22G>A, 35621G>A, KCNH2:rs3815459
C > T
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  HERG; Kv11.1; erg1
PharmGKB Accession Id: PA212

Details

Cytogenetic Location: chr7 : q36.1 - q36.1
GP mRNA Boundary: chr7 : 150642044 - 150675402
GP Gene Boundary: chr7 : 150639044 - 150685402
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Note: The KCNH2 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand; therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

The KCNH2 gene, or human Ether-a-go-go Related Gene (hERG), codes for a potassium voltage gated ion channel [Articles:14999113, 7736582]. The current through the channel is termed the rapid component of the cardiac delayed rectifier (I Kr). The gene is located on chromosome 7 and has 15 exons. Mutations and variants of KCNH2 are one cause of the congenital long QT syndrome (LQTS), a rare syndrome that carries an increased risk of cardiac arrhythmias, including the polymorphic ventricular tachycardia termed torsades de pointes (TdP), which can be fatal [Articles:17143043, 16554806]. There has also been an association between KCNH2 variants and sudden infant death syndrome (SIDS) [Article:947572]. Variants in many other genes can cause congenital LQTS (see, for example, OMIM KCNQ1, OMIM KCNE2, and OMIM SCN5A). However, the syndrome of drug-induced LQTS is most often caused by the block of the hERG channels encoded by the KCNH2 gene.[Articles:18447395, 17143043, 16554806, 12747773, 7736582]. Other mechanism for drug-associated QT prolongation and Tdp have been reported [Articles:18447395, 8873679]. In addition, other conditions, such as heart block or severe electrolyte abnormalities, can also cause QT prolongation and TdP; collectively, the drug-induced and other forms are termed the acquired LQTS (aLQTS).

For the remainder of this summary, the gene KCNH2 and the encoded protein, hERG, will be used interchangeably.

There are more than 100 reported mutations of the KCNH2 gene related to congenital LQTS. See, for example, external websites: OMIM KCNH2, connections for heart hERG polymorphisms, connections for heart hERG mutations, LQTS db hERG mutations. In addition, gene deletions and duplications have been seen in patients with congenital LQTS [Articles:18774102, 16399053].

However, there are very few variants and amino acid changes that have been clearly associated with drug-induced hERG-related LQTS. For example, K897T (rs1805123) has been shown, in several studies, to be associated with longer [Articles:15746444, 14499861],or shorter QT intervals [Articles:10862094, 12829173, 19019189]. K897T was also shown to create a phosphorylation site that inhibited channel activity, independent of drug binding [Article:18791070]. But, the impact of common KCNH2 polymorphisms, including K897T as well as P967L, R1047L (rs36210421) and Q1068R were found to have no significant differences in cisapride IC50 values or Hill coefficients (compared to wild-type) for inhibition of the encoded current by the prototypical blocker cisapride [Article:14975928].

A number of studies have strongly supported the idea that variation not only in KCNH2 but also in other cardiac ion channel and associated genes may predispose to aLQTS. Yang et al [Article:11997281] found that approximately 5% to 10% of individuals with drug-induced TdP actually may have congenital LQTS with rare LQTS-associated channel mutations. This study also identified R784W (rs12720441 ) in patients with drug-associated (amiodarone) TdP [Article:11997281]. In addition, Kannankeril, et al [Article:15851285] found that quinidine prolongs terminal repolarization in family members of patients with drug-induced long QT syndrome, but not in family members of patients who safely tolerate chronic therapy with QT-prolonging drugs

Virtually all drugs that cause drug-induced QT prolongation are KCNH2/I Kr blockers [Articles:12747773, 16554806]. Eight drugs (astemizole, sertindole, terfenadine, cisapride, grepafloxacin, terodiline, lidoflazine, levomethadyl) have been removed from the market because of the risk of aLQTS and fatal TdP [Articles:15718164, 14999113]; and a ninth, droperidol, has received highly restrictive labeling [Article:14999113].

As a result of these events, testing for hERG blocking activity and subsequent evaluations for QT interval prolonging potential are routine in the pharmaceutical industry and such screening has resulted in the halting of drug development of compounds that exhibit these potentially undesirable effects. [Articles:11166255, 16554806]

The list of QT-prolonging drugs and hERG/I Kr inhibitors is large and diverse:

QT-prolonging drugs:
Arizona CERT list of QT-related drugs (may or may not be hERG-related)
Swiss Association hERG list of QT-related drugs


Inhibitors of hERG/I Kr
amiodarone[Article:11997281]; astemizole [Articles:15090000, 10376921, 14999113, 15718164, 16253929] and its metabolite desmethylastemizole [Article:10376921]; cisapride [Articles:18987434, 15090000, 9374794, 14999113, 15718164, 16253929], disopyramide [Article:14624285]; dofetilide [Articles:15522280, 11698075]; erythromycin [Articles:16614168, 18701618] ; fluoxetine [Article:11805215]; grepafloxacin [Articles:15090000, 14999113, 15718164, 16253929]; haloperidol IC50~63nM [Article:16278312]; hydroxyzine [Article:19057127]; ibutilide[Article:14624285]; levomethadyl [Articles:14999113, 16253929]; lidoflazine IC50<37nM [Articles:16278312, 14999113]; methadone[Article:17329992]; mibefradil [Article:16253929]; moxifloxacin[Article:16614168]; perhexiline[Article:18701618] ; pimozideIC50~18nM [Article:12176106]; prenylamine IC50~590nM [Article:16278312] ; probucol[Article:15043509] ; quinidine [Articles:14624285, 18701618]; risperidone IC50 ~167nM [Article:12176106]; sertindole IC50~3nM [Article:12176106], IC50~210nM [Article:16278312]; sotalol [Articles:14624285, 18701618]; telithromycin [Article:16614168]; terfenadine IC50<52nM [Article:16278312], [Articles:18987434, 15090000, 14999113, 16253929]; terodiline [Articles:15090000, 14999113, 15718164]; thioridazine IC50~191nM [Article:12176106], IC50~224nM [Article:16051556]; ziprasidone IC50~169nM [Article:12176106]


Weak inhibitors of hERG/I Kr (IC50>1uM)
arsenic trioxide Kr ~300uM [Article:16278312]; chlorpheniramine IC50~13uM [Article:16278312]; cimetidine IC50>10uM [Article:16278312]; doxepin IC50~4uM [Article:17560554]; loratadine IC50~4uM [Article:16278312]; lovastatin IC50~7uM [Article:16278312]; olanzapine IC50~6013 nM [Article:12176106]; pentamidine Iherg~1mM [Article:16278312]; procainamide] IC50~139 uM [Article:12804575]; pyrilamine IC50~6uM [Article:16278312]; quetiapine IC50~5765 nM [Article:12176106]; sparfloxacin (fluoroquinolone) IC50 ~18 uM [PMIDs:11125032, 12176106]

drugs that prolong QT interval by reducing cell surface KCNH2 expression:
pentamidine [Article:15711592]; arsenic trioxide [Article:15213294].

KCNH2 haplotypes have been reported to modulate variability in the QT interval in population studies [Articles:19305409, 15746444, 19305408]

Citation KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, Thorn Caroline F, Roden Dan M, Klein Teri E, Altman Russ B. PubMed
History

Submitted by Connie Oshiro, Caroline Thorn

Variant Summaries rs12720441, rs1805123, rs36210421, rs3807375, rs3815459
Drugs
Diseases

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Curated Information ?

Publications related to KCNH2: 60

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exome Sequencing Implicates an Increased Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome. Journal of the American College of Cardiology. 2014. Weeke Peter, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Current pharmacogenomic studies on hERG potassium channels. Trends in molecular medicine. 2013. He Fa-Zhong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and alpha,beta-ADR Blocker Response in EH Patients in China. PloS one. 2013. He Fazhong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. The pharmacogenomics journal. 2012. Ramirez A H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug- and non-drug-associated QT interval prolongation. British journal of clinical pharmacology. 2010. van Noord Charlotte, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clinical pharmacology and therapeutics. 2010. Morganroth J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common candidate gene variants are associated with QT interval duration in the general population. Journal of internal medicine. 2009. Marjamaa A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nature genetics. 2009. Newton-Cheh Christopher, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. Journal of pharmacological sciences. 2008. Sakaguchi Tomoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular determinants of hERG channel block by terfenadine and cisapride. Journal of pharmacological sciences. 2008. Kamiya Kaichiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Molecular pharmacology. 2008. Perrin Mark J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proceedings of the National Academy of Sciences of the United States of America. 2008. Gentile Saverio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hERG potassium channels and the structural basis of drug-induced arrhythmias. Chemical research in toxicology. 2008. Mitcheson John S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). European heart journal. 2008. Sinner Moritz F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel. Life sciences. 2008. Jo Su-Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations. BMC medical genetics. 2008. Zhang Xianqin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current medicinal chemistry. 2008. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenetics and genomics. 2007. Spraggs Colin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation. 2007. Newton-Cheh Christopher, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. European journal of human genetics : EJHG. 2007. Gouas L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochemical pharmacology. 2007. Duncan R S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical pharmacology and therapeutics. 2007. Eap C B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function. The Journal of biological chemistry. 2007. Nakajima Tadashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Drug-induced long QT and torsade de pointes: recent advances. Current opinion in cardiology. 2007. Kannankeril Prince J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. The Journal of pharmacology and experimental therapeutics. 2006. Wisialowski Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hERG potassium channels and cardiac arrhythmia. Nature. 2006. Sanguinetti Michael C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. The Journal of pharmacology and experimental therapeutics. 2006. Katchman Alexander N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Fitzgerald Patrick T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pentamidine reduces hERG expression to prolong the QT interval. British journal of pharmacology. 2005. Cordes Jason S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circulation research. 2005. Pfeufer Arne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Kannankeril Prince J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive in silico modeling for hERG channel blockers. Drug discovery today. 2005. Aronov Alex M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The phenothiazine drugs inhibit hERG potassium channels. Drug and chemical toxicology. 2005. Kim Ki-Suk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. Journal of molecular and cellular cardiology. 2004. Sun Zhuoqian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clinical science (London, England : 1979). 2004. Hayashi Kenshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedeberg's archives of pharmacology. 2004. Zitron Edgar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular pharmacology. 2004. Ficker Eckhard, et al. PubMed
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. American journal of physiology. Heart and circulatory physiology. 2004. Anson Blake D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced torsades de pointes and implications for drug development. Journal of cardiovascular electrophysiology. 2004. Fenichel Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Drug-induced prolongation of the QT interval. The New England journal of medicine. 2004. Roden Dan M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003. Kupershmidt Sabina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide. Biochemical and biophysical research communications. 2003. Ridley John M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. Journal of medicinal chemistry. 2003. Pearlstein Robert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American journal of therapeutics. 2003. Cubeddu Luigi X. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. PubMed
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002. Yang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. The Journal of pharmacology and experimental therapeutics. 2002. Thomas Dierk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. European journal of pharmacology. 2001. Finlayson K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2000. Mitcheson J S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of cardiovascular electrophysiology. 1999. Zhou Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999. Abbott G W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation. 1999. Priori S G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. The American journal of physiology. 1997. Mohammad S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. 1996. Roden D M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995. Schwartz P J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995. Sanguinetti M C, et al. PubMed

LinkOuts

UniProtKB:
KCNH2_HUMAN (Q12809)
Ensembl:
ENSG00000055118
GenAtlas:
KCNH2
GeneCard:
KCNH2
MutDB:
KCNH2
ALFRED:
LO024124N
HuGE:
KCNH2
Comparative Toxicogenomics Database:
3757
ModBase:
Q12809
HumanCyc Gene:
HS00680
IUPHAR Receptor:
Kv11.1 (572)
HGNC:
6251

Common Searches